HDL-c is a powerful lipid predictor of cardiovascular diseases

被引:41
作者
Bruckert, E. [1 ]
Hansel, B. [1 ]
机构
[1] Hop La Pitie Salpetriere, Inst Endocrinol & Prevent Cardiovasc Dis, AP HP, F-75651 Paris 13, France
关键词
D O I
10.1111/j.1742-1241.2007.01509.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Relationship between HDL-c and cardiovascular diseases: Beyond the role of low-density lipoprotein cholesterol (LDL-c) in the development of atherosclerosis, growing evidence suggest that high-density lipoprotein cholesterol (HDL-c) is a powerful predictor of cardiovascular disease. Indeed, epidemiological, mechanistic and intervention studies suggest that low HDL-c is a major cardiovascular risk factor and that increasing HDL-c plasma levels may be beneficial, particularly in patients with low HDL-c levels. The inverse association between HDL-c concentrations and cardiovascular risk is continuous without threshold value. Thus, any categorical definition of low HDL-c is arbitrary. Protective effects of HDL: HDL particles are highly heterogeneous in structure and intravascular metabolism. Antiatherogenic properties of HDL include its role in the reverse cholesterol transfer, besides its antioxidant, anti-inflammatory and antiapoptotic activities. What should clinicians do? From a practical point of view, HDL-c should be systematically measured to assess the cardiovascular risk in patients. The first step to consider in subjects with low HDL-c is to look for specific causes and give advice to change inappropriate lifestyle components associated with low HDL-c, such as smoking, lack of physical exercise and overweight. Patients with very low HDL-c need a thorough evaluation by specialist physicians. Statins are associated with a modest increase of HDL-c (5%) while fibrates and nicotinic acid increase HDL-c by 10% and 20% respectively. © 2007 The Authors.
引用
收藏
页码:1905 / 1913
页数:9
相关论文
共 44 条
[1]  
AGMON J, 1992, CIRCULATION, V86, P839
[2]  
ASSMANN G, 1993, CIRCULATION, V87, P28
[3]  
ASSMANN G, 1996, ATHEROSCLEROSIS, V124, P11
[4]   LpA-1, LpA-I:A-II HDL and CHD-risk:: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial [J].
Asztalos, Bela F. ;
Demissie, Serkalem ;
Cupples, L. Adrienne ;
Collins, Dorothea ;
Cox, Caitlin E. ;
Horvath, Katalin V. ;
Bloomfield, Hanna E. ;
Robins, Sander J. ;
Schaefer, Ernst J. .
ATHEROSCLEROSIS, 2006, 188 (01) :59-67
[5]  
AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917
[6]   Lecithin: cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up [J].
Ayyobi, AF ;
McGladdery, SH ;
Chan, S ;
Mancini, GBJ ;
Hill, JS ;
Frohlich, JJ .
ATHEROSCLEROSIS, 2004, 177 (02) :361-366
[7]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[8]   Unique lipoprotein phenotype and genotype associated with exceptional longevity [J].
Barzilai, N ;
Atzmon, G ;
Schechter, C ;
Schaefer, EJ ;
Cupples, AL ;
Lipton, R ;
Cheng, S ;
Shuldiner, AR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (15) :2030-2040
[9]   Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds - A meta-analysis of randomized controlled trials [J].
Birjmohun, RS ;
Hutten, BA ;
Kastelein, JJP ;
Stroes, ESG .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (02) :185-197
[10]   Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol [J].
Brousseau, ME ;
Schaefer, EJ ;
Wolfe, ML ;
Bloedon, LT ;
Digenio, AG ;
Clark, RW ;
Mancuso, JP ;
Rader, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1505-1515